Abstract
In 2023, Finland faced an outbreak of highly pathogenic avian influenza caused by clade 2.3.4.4b A(H5N1) viruses, which spread from wild birds to fur farms. Vaccinations of individuals at-risk, such as fur and poultry farm workers, veterinarians, and laboratory workers, began in June 2024 using the MF59-adjuvanted inactivated (H5N8) vaccine manufactured by Seqirus (based on clade 2.3.4.4b A/Astrakhan/3212/2020). We investigated antibody responses following a two-dose vaccination regimen in 39 subjects. Vaccination induced comparable levels of functional antibodies both against the vaccine virus and two clade 2.3.4.4b viruses, either associated with outbreaks in fur animals in Finland or cattle in the United States. Upon two doses of the vaccine for previously unvaccinated people, the seroprotection rate against the vaccine virus was 83 % (95 % CI 70-97 %, titer ≥20) and 97 % (95 % CI 90-100 %, titer ≥40) using microneutralization or hemagglutinin inhibition assays, respectively. In a subset of previously H5-vaccinated individuals, the first dose already led to seroprotective titers, indicative of immunological recall. These data show that the vaccine is expected to confer cross-protection against currently circulating H5 clade 2.3.4.4b viruses.
Competing Interest Statement
Hanna Nohynek is member of the National Immunization Technical Advisory Group, THL, Finland and chair of the WHO Strategic Advisory Group of Experts. Ritva Syrjanen has acted or acts as sub-investigator in a COVID-19 study sponsored by Pfizer, pneumococcal carriage study sponsored by Merck Sharp & Dohme and influenza, pertussis and meningitis studies sponsored by Sanofi Pasteur, not related to this work. Her current affiliation FVR, Finnish Vaccine Research conducts clinical trials and studies sponsored by almost all vaccine providers, not related to this work. Merit Melin is member of the National Immunization Technical Advisory Group, THL, Finland.
Clinical Protocols
https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-509178-44-00
Funding Statement
The Finnish Institute for Health and Welfare (THL) funded the clinical vaccine study. For the immunological studies THL and University of Turku received funding from the Academy of Finland, Avian and seasonal influenza vaccine-induced humoral and cell-mediated immune responses, Decision number 362192 and 362193.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki and was submitted for evaluation through the EU Clinical Trial Information System. The study has been approved by the National Committee on Medical Research Ethics (decision number TUKIJA/7/2024) and received authorization from the Finnish Medicines Agency Fimea (EU CT number 2023-509178-44-00).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Data subject to third party restrictions. The data that support the findings of this study are available from Finnish Social and Health Data Permit Authority Findata. Restrictions apply to the availability of these data, which were used under license for this study under informed consent form. Anonymized data are available after permission by Findata.
